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doi:10.101A Prospective Study Comparing the Outcomes and
Health-Related Quality of Life in Adult Patients with
Myeloid Malignancies Undergoing Allogeneic
Transplantation Using Myeloablative or
Reduced-Intensity Conditioning
Vikas Gupta,1 Tony Panzarella,2,3 Le Li,2 Jabeen Khan,1 Ajay Sharma,1
Jeffrey H. Lipton,1 John Kuruvilla,1 Hans Messner,1 Shabbir M. H. Alibhai4We compared the outcomes including health-related quality of life (HRQOL) in adult patients undergoing al-
logeneic transplantation usingmyeloablative conditioning (MAC) or reduced-intensity conditioning (RIC). This
outcome study was a nonrandomized, prospective, observational noninferiority study, and primarily designed
to determine whether RIC was as effective as MAC for myeloid malignancies. Comprehensive longitudinal as-
sessment of HRQOLwas done at baseline, day 30, day 100, day 180, and day 365 using validated instruments. A
total of 115 patients (MAC, 51; RIC, 64) participated in this study.Of these 115 patients, 105 (91%) participated
for HRQOL assessments. Themain indication for HCTwas acute myeloid leukemia (72%). Except age (median
41 vs 59 years, P\.0001), baseline characteristics were similar in patients undergoing MAC and RIC, respec-
tively. Progression-free survival (PFS) at 1 year was 59% (SE5 7%) and 53% (SE5 6%) for the patients under-
going MAC and RIC, respectively (90% confidence interval [CI] 29% to 121%, P 5 .53). No significant
difference in overall survival (OS), cumulative incidents of acute and chronic graft-versus-host disease (aGVHD,
cGVHD), nonrelapsemortality (NRM) or relapsewas observed in the 2 cohorts. The trajectory of decline and
recovery of HRQOL was similar between the 2 cohorts. We conclude that clinical outcomes and HRQOL in
patients with myeloid malignancies undergoing RIC are not inferior to MAC at 1 year.
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6/j.bbmt.2011.05.022malignancies undergoing allogeneic hematopoietic
cell transplantation (HCT) [1,2]. These regimens
have extended the application of HCT to older
patients and to those with significant comorbidities
who otherwise would have precluded their candidacies
for transplantation. Several retrospective studies have
compared the outcomes of myeloablative conditioning
(MAC) and RIC in patients with myeloid malignancies.
Despite a significantly higher proportion of older
patients in the RIC cohorts, these studies have reported
similar survival outcomes after RIC and MAC [3-12].
Major limitations of these studies include lack of
information on the decision process for the selection of
RIC regimens and comorbidity data. Importantly, none
of these studies have compared health-related quality of
life (HRQOL) in patients undergoing RIC or MAC.
RIC regimens are mainly offered to older patients
and those with significant comorbidities. Because of
anticipated lower regimen-related toxicities with
RIC, these patients may have better HRQOL in the
immediate posttransplantation period. However, older113
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nerable to other posttransplantation complications,
such as infections and graft-versus-host disease
(GVHD), resulting in detrimental impact onHRQOL.
This has raised concern over the HRQOL of these
older patients to younger and fitter patients undergo-
ing MAC. In addition, patients undergoing MAC or
RIC HCT are at different competing risks of
transplant-related mortality and relapse, and the over-
all impact of these posttransplantation complications
on HRQOL is not well understood. The majority of
HRQOL data in patients undergoing HCT are cross-
sectional and limited to long-term survivors [13-16].
Only limited information is available on the
comparative HRQOL in patients treated with MAC
versus RIC regimens [17,18], and more longitudinal
data would be desirable.
We undertook a prospective study at our center in
patients with myeloid malignancies undergoing HCT
to compare the clinical outcomes and longitudinal
HRQOL of adult patients with myeloid malignancies
undergoing HCT using MAC or RIC.PATIENTS AND METHODS
Eligibility Criteria
The study was approved by the research and ethics
board of the University Health Network, Toronto
(REB # 05-0912-CE). The inclusion criteria for the
study were: adult patients 18 to 70 years old, undergo-
ing HCT for a myeloid malignancy using a matched
related or unrelated donor. Patients with acute mye-
loid leukemia (AML) with active disease at the time
of HCT were excluded.Study Design
This was a nonrandomized, prospective, observa-
tional noninferiority study and primarily designed to
determine whether RIC was as effective as MAC for
the treatment of myeloid malignancies. The primary
endpoint of the study was progression-free survival
(PFS) at 1 year from the date of HCT. The study
was designed to accept RIC as noninferior to MAC if
the 1-year PFSwas within 0.15 of theMAC arm.Using
a 1-sided Type I error of 0.10, a sample size of 110 (55
per arm) was required to have a power of 0.8 so that the
upper level of the 90% confidence limit would not
exceed 0.15. Secondary endpoints were longitudinal
HRQOL, overall survival (OS), regimen-related toxic-
ities, acute GVHD (aGVHD) and chronic GVHD
(cGVHD), cumulative incidence of relapse, and
nonrelapse mortality (NRM).
Informed consent was obtained from all the pa-
tients. In addition to the consent for clinical outcomes,
patients were asked to sign a separate consent for theHRQOL study. For participation in the HRQOL
study, fluency in English was required. However,
where validated translations of both the European
Organization for Research and Treatment of Cancer
(EORTC) core 30-item questionnaire (QLQ-C30)
and the Functional Assessment of Cancer Therapy–
anemia and fatigue subscale (FACT-An) were available
in the patient’s language and a translator was available,
the patient was eligible for recruitment.
Patient Accrual
From January 2005 to September 2008, 118 patients
who met the eligibility criteria underwent HCT at the
Blood and Marrow Transplant Program of Princess
Margaret Hospital, Toronto. Of these, 115 patients
consented to participate in the outcomes study.Of these
115 participants, 105 (91%) also consented to partici-
pate in the HRQOL assessments. The reasons for non-
participation in the HRQOL study were: time
commitment, 5; language barrier, 3; and others, 2.
Conditioning Regimens, GVHDProphylaxis, and
Supportive Care
All the cases were discussed in a transplant meet-
ing, and intensity of the conditioning was decided on
the basis of the consensus of this meeting. There was
a consensus among the physicians to offer RIC to
patients $60 years old and MAC to those\40 years
old. Between 40 and 59 years, further factors such as
comorbidities, performance status, and previous
HCT were taken into consideration, and conditioning
intensity was decided according to group consensus.
All the transplantations were performed as in-patient
irrespective of type of conditioning. The intensity of
the conditioning regimen was defined according to
the criteria defined by Center for International Blood
and Marrow Transplant Research (CIBMTR) [19].
MAC regimens included: cyclophosphamide (120
mg/kg) and 1200 cGy total body irradiation (TBI) in
6 fractions (n 5 18); i.v. busulphan (12.8 mg/kg) and
cyclophosphamide (120 mg/kg) (n 5 4); cytarabine,
cyclophosphamide, and TBI (n 5 4); and fludarabine
(200 mg/m2) and i.v. busulphan (12.8 mg/kg) with
(n5 21) or without (n5 4) 400 cGYTBI in 2 fractions.
The RIC regimen comprised of intravenous fludara-
bine (120 mg/m2), and i.v. busulphan 6.4 mg/kg with
(n 5 59) or without (n 5 5) low-dose TBI (2 cGy).
Hematopoietic progenitor cells were infused on day 0.
Postallograft, granulocyte-colony stimulating factor
(G-CSF) was not routinely administered to the recip-
ients. The GVHD prophylaxis was performed with
cyclosporine and methotrexate or cyclosporine and
mycophenolate for the related donors, and cyclospor-
ine and low-dose alemtuzumab for the unrelated
donors [20]. The supportive care was provided as
described previously [21].
Biol Blood Marrow Transplant 18:113-124, 2012 115Outcomes and QOL after Myeloablative or RICRegimen-Related Toxicities (RRT)
RRT were evaluated according to Bearman
Toxicity Criteria [22]. Toxicities were scored at the
completion of the conditioning regimen, and then
once a week for the first 6 weeks from day 0. For com-
parisons between MAC and RIC, the worst toxicity
grade was evaluated.
Definitions and Evaluation of Response
Disease risk was defined as high or standard risk on
the basis of the following disease-based criteria. For
AML, high-risk was defined as patients having at least
1 of the following criteria: poor risk cytogenetics as
defined by SWOG/ECOG [23], .1 course of inten-
sive induction to achieve complete remission (CR)
[24], a preceding myelodysplastic syndrome (MDS)/
myeloproliferative disorder (MPD), therapy-related
AML (t-AML), second remission AML with CR1\1
year. High-risk MDS was defined as therapy-related–
MDS or a score of$1.5 according to the International
Prognostic Scoring System (IPSS) [25]. A Lille score of
2 for myelofibrosis [26] and CML patients other than
first chronic phase were defined as high risk. All other
patients were defined as standard risk. Comorbidities
were scored according to the HCT-specific index, and
severity was graded as none (score 0), mild (score 1),
moderate (score 2), and severe (score$3) as previously
defined [27]. Hematopoietic recovery, aGVHD, and
cGVHD was defined as previously described [21].
PFS was calculated from the date of BMT to relapse
or progression of disease, death from any cause, or
last follow-up. OS was calculated from date of bone
marrow transplantation (BMT) to death or last
follow-up. NRM was defined as death in continuous
remission, and relapse was defined as hematologic re-
currence of the disease in blood, BM, or extramedul-
lary site. The data were collected prospectively in the
case report forms specifically designed for the study
and crosschecked for accuracy.
HRQOL Instruments
Comprehensive assessment of HRQOL was done
at baseline, day 30, day 100, day 180, and day 365. Gen-
eral QOL, treatment-relevantQOL, and related symp-
toms such as fatigue were assessed by the following
measures: EORTCQLQ-C30 [28], FACT-BoneMar-
row Transplantation (FACT-BMT) [29], FACT-An
[30], Hospital Anxiety and Depression Scale (HADS)
[31], and Lawton and Brody’s instrumental activities
of daily living (IADL) [32]. The EORTC QLQ-C30
is a multidimensional scale that features 5 functional
scales (physical, role, cognitive, emotional, and social),
3 symptom scales (fatigue, pain, and nausea/vomiting),
several single-item symptom subscales (appetite, sleep
disturbance, dyspnea, constipation, and diarrhea),
and a global QOL measure [28]. FACT-BMT isa 12-item subscale widely used to measure
transplant-related QOL in malignant hematology
[29]. The FACT-An is a 20-item questionnaire
(13 items on fatigue and 7 items on other aspects of
anemia) designed specifically to explore fatigue in
cancer patients [30]. HADS is a 14-item question-
naire and includes 2 validated subscales measuring
nonsomatic symptoms of depression and anxiety
[31]. IADL measures are sensitive to the impact of
cancer and its treatment [32].
Assessments were done in a quiet room in the clinic
area or, if the patient preferred, via mail-in question-
naires that were completed at home. The first ques-
tionnaire at baseline was distributed by the study
coordinator/treating physician, and follow-up ques-
tionnaires were given to patients at the follow-up
appointments or mailed to the home address. If an
evaluation was not completed, reasons for noncomple-
tion were captured.
The difference in HRQOL between the 2 co-
horts was considered clinically meaningful when
a moderate-sized difference in the HRQOL scores
was supported by a P value of\.05. Moderate-size
differences for the various instruments were defined
using published cutoffs where possible or moderate
effect sizes otherwise, as follows: EORTC-QLQ-
C30, 10 points on transformed scales [33]; FACT-
BMT, 3 points on a 10-item (40-point) scale [29,34];
FACT-An subscale, 4 points on a 20-item (80-point)
scale [35]; FACT-fatigue subscale, 3 points on a 13-
item (52 point) scale [35]; HADS, 1.5-2.0 points on
each 7-item anxiety and depression subscale [34];
and IADL, 1 point on a 17-point scale [32].Statistical Analysis
Descriptive statistics were reported using the
median and range or the mean and standard deviation
for continuous variables and using frequencies and pro-
portions for categoric variables. PFS and OS were cal-
culated using the Kaplan-Meier method. Cumulative
incidents of NRM, relapse, aGVHD, and cGVHD
were calculated to account for competing risks [36].
Differences between survival curves were analyzed
using the log-rank test. Differences between cumula-
tive incidence curves were analyzed by Gray’s test.
Cox proportional hazards regression was applied to
multivariable analyses.
Treatment group comparisons over time using
within-patient changes in quality of life (ie, improved,
unchanged, or worse) were tested using the Fisher ex-
act test. Mean QOL scores at baseline and at 1 year
were compared using the 2-sample t test.
The general linear mixed effects linear regression
model was used to test the effect of treatment over
time for each QOL measure [37]. The variables treat-
ment, time, treatment  time interaction, and other
Table 1. Baseline Patient, Disease, and Transplant-Related
Characteristics of Patients Undergoing Myeloablative or
Reduced-Intensity Conditioning
Characteristics
MAC (%)
n 5 51
RIC (%)
n 5 64 P value
Median age, yrs (range) 41 (21-60) 59 (43-69) <.0001
Age <.0001
#40 years 25 (49) 0
41-59 years 25 (49) 36 (56)
$60 years 1 (2) 28 (44)
Proportion of male patients 29 (57) 34 (53) .69
KPS at BMT .16
$90 50 (98) 59 (92)
<90 1 (2) 5(8)
HCT-specific comorbidity score .30
None/mild (0/1) 24 (47) 21 (33)
Moderate (2) 8 (16) 13 (20)
Severe ($3) 19 (37) 30 (47)
Disease .47
AML 34 (67) 49 (77)
CR1 21 34
CR2 13 15
MDS 8 (16) 8 (12)
Other myeloid 9 (18) 7 (11)
Disease risk .86
High 39 (76) 48 (75)
Standard 12 (24) 16 (25)
Significant fungal infection
before BMT 10 (24) 15 (26) .78
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unstructured variance-covariance error term was as-
sumed inmodeling theHRQOLmeasurements within
each patient across time. The test of the interaction
effect involving treatment and time was never found
to be statistically significant, so it was dropped from
subsequent models.
Missing HRQOL data were computed in several
ways and compared to results without imputation. Be-
cause missing HRQOL data was related to deteriorat-
ing patient outcome, imputation involved (1) assigning
the worst HRQOL scores to patients who were still
alive, (2) assigning the median score from the worst
quartile to patients who were still alive, and (3) assign-
ing the worst HRQOL score to all patients with miss-
ing data (alive or dead). Because the results were
similar, only the nonimputed results are reported here.
All analyses were performed in SAS version 9.2
(SAS Institute, Cary, NC), except for the analysis of
competing risks, which were performed in R version
2.10.1 (R Foundation for Statistical Computing,
Vienna, Austria, 2009; http://www.R-project.org) using
the Cmprsk package.Type of donor .20
MSD 25 (49) 39 (61)
UD 26 (51) 25 (39)
Conditioning regimens —
MAC
CY TBI 18 (35) —
Bu CY 4 (8) —
Ara-C/CY TBI 4 (8) —
Flu Bu TBI 21 (41) —
Flu Bu 4 (8) —
RIC
Flu Bu TBI — 59 (92)
Flu Bu — 5 (8)
CMV serostatus (D/R) .99
neg/neg 20 (39) 25 (39)
Others 31 (61) 39 (61)
Source of hematopoietic cells .48
PB 47 (92) 61 (95)
BM 4 (8) 3 (5)
MAC indicates myeloablative conditioning; RIC, reduced-intensity con-
ditioning; KPS, Karnofsky’s performance status; BMT, blood or marrow
transplantation; AML, acute myeloid leukemia; MDS, myelodysplastic
syndrome; MSD, matched sibling donor, UD, unrelated donor; CMV,
cytomegalovirus; D, donor; R, recipient; PB, peripheral blood; BM,
bone marrow; CY, cyclophosphamide; TBI, total body irradiation; Bu,
busulphan; Ara-C, cytarabine; Flu, fludarabine.RESULTS
Of the 115 study patients, 51 patients underwent
MAC, and 64 patients underwent RIC. The median
age of patients undergoing RICwas significantly higher
compared with those undergoing MAC (59 years vs
41 years, P \ .0001). The main indication of HCT
was AML (72%). Of 64 patients undergoing RIC, 28
(44%) were $60 years and 36 (56%) were between 41
and 59 years. The indications for RIC in patients\60
years were: significant comorbidities (n5 21), previous
HCT (n5 6), poor performance score (n5 3), andmis-
cellaneous (n5 6). Apart from age, other baseline char-
acteristics were similar between the 2 cohorts (Table 1).
There were no significant differences in HCT comor-
bidity scores between the 2 groups (Table 1), including
psychiatric comorbidity (15.7% vs 15.6%).
PFS and OS
PFS at 1 year was 59% (SE 5 7%) and 53%
(SE 5 6%) for the patients undergoing MAC and
RIC, respectively (90% confidence interval [CI] 29%
to 121%, P 5 .53) (Figure 1A). OS at 1 year was 59%
(SE5 7%) and 61% (SE5 6%) for the patients under-
goingMAC andRIC, respectively (P5 .70) (Figure 1B).
In the multivariate analysis, no significant difference in
PFS or OS was observed between the patients undergo-
ing MAC and RIC (Table 2). High-risk disease was the
only significant factor for inferior PFS and OS in the
multivariate analysis (Table 2). In a subgroup analysis,
no significant difference in PFS or OS was observed in
patients age 41 to 59 years (data not shown).RRT
Comparative details of RRT in patients undergo-
ing MAC and RIC are summarized in Table 3. Signi-
ficantly higher stomatitis (P \ .001) and hepatic
(P 5 .02) toxicities were observed in patients under-
going MAC.
Hematopoietic Recovery, aGVHD, and cGVHD
The median duration of neutropenia was signifi-
cantly shorter in the patients undergoing RIC in com-
parison to MAC (12 days vs 17 days, P\ .0001). Ten
Figure 1. Comparisons of patients undergoing myeloablative versus RIC for HCT. (A) PFS. (B) OS. (C) Cumulative incidence of NRM. (D) Cumulative
incidence of relapse.
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platelet counts to\20  109/L. The median days to
platelet count recovery was significantly faster in the
RIC cohort (10 vs 14 days, P 5 .0003). The
cumulative incidence of grade II-IV aGVHD at day
180 was 61% (SE 5 0.5%) and 59% (SE 5 0.4%)
for patients undergoing MAC and RIC, respectively
(P 5 .90). No differences in the cumulative incidence
of grade III-IV aGVHD (18% [SE 5 0.3%] vs 14%
[SE 5 0.2%], P 5 .79) or the proportion of patients
developing steroid-refractory aGVHD (18% vs 8%,
P 5 .16) were observed in patients undergoing MAC
and RIC, respectively. Median time to onset of
aGVHDwas 44 days and 49 days in the patients under-
going MAC and RIC, respectively (P 5 .23). Thecumulative incidence of chronic GVHD at 1 year
was 41 (SE 5 0.5%) and 55 (SE 5 0.5%) in patients
undergoing MAC and RIC, respectively (P 5 .08).
The median days to onset of cGVHD was shorter
in the patients undergoing MAC (182 days vs 214
days, P 5 .02).NRM and Relapses
No significant differences in the cumulative
incidents of NRM (29% [SE 5 6%] vs 25% [SE 5
5%], P 5 .87) and relapse (12% [SE 5 5%] vs 22%
[SE5 5%],P5 .24)were observed in thepatients under-
going MAC and RIC, respectively (Figure 1C and D).
The hazard ratios (HR) for NRM and relapse for the
Table 2. Multivariate Analysis of Progression-Free and Overall Survival
Parameter
PFS OS
HR 95% CI P value HR 95% CI P value
Conditioning intensity .59 .47
MAC 1.00 — 1.00 —
RIC 0.81 0.38-1.74 0.75 0.35-1.63
Age 1.02 0.99-1.06 .26 1.02 0.99-1.06 .26
KPS at BMT .70 .50
$90% 1.00 — —
<90 1.19 0.50-2.86 1.35 0.56-3.23
HCT-specific comorbidity score
None/mild (0/1) 1.00 — —
Moderate (2) 0.61 0.26-1.45 .26 0.56 0.22-1.41 .22
Severe ($3) 1.31 0.73-2.34 .36 1.43 0.78-2.59 .25
Disease risk .017 .008
Standard 1.00 — 1.00 —
High 2.44 1.16-5.00 3.03 1.33-6.67
Donor type
MSD 1.00 — 1.00 —
UD 1.13 0.66-1.94 .66 1.29 0.74-2.25 .36
MAC indicates myeloablative conditioning; RIC, reduced-intensity conditioning; PFS, progression-free survival; OS, overall survival; HR, hazard ratio;
RIC, reduced-intensity conditioning; CI, confidence interval; KPS, Karnofsky’s performance scores; BMT, blood or marrow transplantation; MSD,
matched sibling donor, UD, unrelated donor.
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1.72 (95% CI 0.34-8.86, P5 .51), respectively. No sig-
nificant factors for NRM and relapse were identified in
multivariate analysis.
HRQOL
A total of 105 patients (MAC, 44; RIC, 61)
participated in the HRQOL study. The median ageTable 3. Regimen-Related Toxicities According to Bearman
Toxicity Criteria in Patients Undergoing HCT Using MAC and
RIC Approaches
Organ Toxicity Grade
MAC
n 5 51
RIC
n 5 64 P value
Cardiac toxicity 0 51 62 >.9
1 0 1
$2 0 1
Pulmonary toxicity 0 49 63 .72
1 1 0
$2 1 1
Stomatitis toxicity 0 6 28 <.001
1 5 20
$2 40 16
Gastrointestinal toxicity 0 47 60 .3
1 2 4
$2 2 0
Hepatic toxicity 0 33 55 .02
1 10 4
$2 8 5
CNS toxicity 0 46 62 .26
1 2 0
$2 3 2
Bladder toxicity 0 45 63 .06
1 2 0
$2 4 1
Renal toxicity 0 44 60 .34
1 2 2
$2 5 2
HCT indicates allogeneic hematopoietic cell transplantation; MAC,
myeloablative conditioning; RIC, reduced-intensity conditioning; CNS,
central nervous system.of patients completing HRQOL (59 years vs 42 years,
P\ .0001) was similar to the entire study population.
No differences in baseline characteristics were found
between the participants and nonparticipants in the
HRQOL study (data not shown). Compliance with
completion of HRQOL assessments among surviving
patients was high; reasons for noncompletion at vari-
ous study time points are summarized in Table 4.
Baseline HRQOL Scores
Mean HRQOL scores at baseline for the 2 cohorts
are shown in Table 5. Mean QOL scores were similar
at baseline, except for a higher score in role function-
ing for the RIC cohort (67.2 vs 54.8, P 5 .05).
Posttransplantation HRQOL Scores
Except emotional functioning, there was a decline
in various domains of HRQOL in the posttransplanta-
tion period, with the lowest scores at day 30 followed by
subsequent slow improvement toward baseline by day
365 (Figures 2 and 3). This pattern was similar for
patients undergoing MAC and RIC, respectively. The
trajectory for post-HCT HRQOL scores for various
domains of the QLQ-C30, FACT-An, and FACT-
BMT is shown in Figures 2 and 3, respectively. The
change in HRQOL status at each time point in
comparison to baseline values for patients undergoing
MAC and RIC for the study instruments are shown in
Table 6. In Table 6, change inHRQOL status is shown
where data is available for both time points, and the re-
sults reflect changes in QOL between them.
The RIC cohort had better QLQ-C30 scores
in the domains of physical functioning at day 30
(Figure 2B, 75 vs 63, P 5 .006). A higher proportion
of patients undergoing RIC had worsening of
Table 4. Compliance for Completion of HRQOL Assessments and Reasons for Noncompletion
Baseline Day 30 Day 100 Day 180 Day 365
Alive 105 104 96 82 64
Completed evaluations 103 (98%) 95 (91%) 82 (85%) 70 (85%) 54 (84%)
Reasons for noncompletion of QOL assessment
Sick because of toxicity or disease relapse 1 6 8 8 3
Consent with drawn 0 1 3 3 2
Others 1 2 3 1 5
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ward (Figure 2e and Table 6). The absolute difference
in cognitive function was small at day 100 (86 vs 80,
P 5 .13), day 180 (84 vs 76, P 5 17), and 365 (79 vs
75, P 5 .48) in patients undergoing MAC and RIC,
respectively (Figure 2E).
Data were also reanalyzed in a sensitivity analysis
after imputing lowest quintile scores for the patients
who did not complete HRQOL assessments because
of sickness resulting from transplant-related toxicities
or relapse. Imputing these data did not significantly
influence the above results (data not shown).
In an exploratory analysis, we compared the
cognitive scores in patients age 41 to 59 years undergo-
ing MAC and RIC, respectively. No difference in
cognitive scores between MAC and RIC cohorts wasTable 5. Health-Related Quality-of-Life Scores at Baseline and 12 M
Instrument Myeloablative Condi
EORTC QLQ-C30
Global health status scale
Baseline score, mean (SD) 64.9 (21.7)
Change (*) (SD) at 12 months from baseline +2.7 (32.4)
Functioning scales
Physical
Baseline score, mean (SD) 81.3 (15.9)
Change (SD) at 12 months from baseline 22.1 (30.5)
Role
Baseline score, mean (SD) 54.8 (34.4)
Change (SD) at 12 months from baseline +8.3 (43.6)
Social
Baseline score, mean (SD) 54.8 (32.4)
Change (SD) at 12 months from baseline +18.9 (38.9)
Cognitive
Baseline score, mean (SD) 77.8 (20.7)
Change (SD) at 12 months from baseline +3.8 (19.9)
Emotional
Baseline score, mean (SD) 70.2 (19.5)
Change (SD) at 12 months from baseline +0.4 (28.5)
FACT-An
Baseline score, mean (SD) 57.6 (13.1)
Change (SD) at 12 months from baseline 21.4 (23.1)
FACT-BMT
Baseline score, mean (SD) 27.7 (5.6)
Change (SD) at 12 months from baseline 20.8 (7.8)
HADS-Anxiety
Baseline score, mean (SD) 6.9 (4.5)
Change (SD) at 12 months from baseline 21.2 (4.5)
HADS-Depression
Baseline score, mean (SD) 4.6 (2.6)
Change (SD) at 12 months from baseline 20.7 (3.5)
IADL
Baseline score, mean (SD) 14.1 (3.4)
Change (SD) at 12 months from baseline 20.6 (4.1)
*Change scores are based on observations that have measurements at 365 daseen at baseline (75 vs 81, P 5 .28). Cognitive scores
were worse at day 30 (60 vs 74, P 5 .04), better at
day 180 (87 vs 71, P 5 .04) for patients undergoing
MAC, and similar at other time points (data not
shown).DISCUSSION
In this prospective studyation, we show that de-
spite a higher proportion of older patients in the RIC
cohort, survival outcomes between the 2 approaches
were similar in patients with myeloid malignancies.
The prospective nature of the study gave us an oppor-
tunity to compare the HRQOL in addition to clinical
outcomes. These clinical outcome results are similaronths Posttransplantation
tioning Reduced-Intensity Conditioning P-Value
67.2 (20.8) .58
22.4 (28.4) .55
84.4 (15.9) .33
24.1 (22.4) .12
67.2 (29.3) .051
+3.8 (38.4) .51
60.1 (24.2) .37
+7.0 (32.4) .23
83.9 (19.2) .13
212.4 (18.2) .004
74.0 (20.8) .36
+9.0 (20.3) .21
59.4 (13.2) .49
24.2 (15.9) .60
27.7 (5.7) .98
0.5 (6.1) .51
5.8 (3.5) .17
21.0 (3.9) .87
4.1 (2.7) .36
0.4 (3.7) .29
12.8 (3.8) .07
0.1 (4.6) .56
ys and at baseline.
Figure 2. Longitudinal comparisons of HRQOL of patients undergoing myeloablative versus RIC in various domains of EORTC-QLQ-C30. (A) Global
QOL score. (B) Physical functioning. (C) Role functioning. (D) Social functioning. (E) Cognitive functioning. (F) Emotional functioning.
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various myeloid malignancies [3,7-11,38]. A high
peritransplantation mortality has been a major
barrier to the use of MAC in older patients [39,40].
No adverse impact of age on any of the major
outcomes was observed in our study, indicating that
outcomes similar to younger patients can be achieved
in older patients treated with RIC, who are not
considered suitable candidates for MAC. In the
multivariate analysis, the only factor influencing the
survival outcomes was disease biology, as patients
with high-risk disease had inferior outcomes irrespec-
tive of conditioning therapy. Similar results were also
recently reported in an European Blood and Marrow
Transplant Group retrospective study in patients
with MDS and secondary AML [8].
Unlike other studies, we did not observe any
significant difference in relapse rate among patientsundergoing RIC compared withMAC. Several reasons
may explain this observation. The RIC protocol used
at our center would be considered on the higher end
of the intensity spectrum of RIC. The main indication
for HCTwas AML in CR1 and CR2. It is possible that
for patients in CR, graft-versus-leukemia (GVL) effect
is more important rather than intensity of condition-
ing therapy [3,11]. Similarly, NRM in the RIC
group was not lower than that with MAC, and this
may be because of differences in the median age
(almost 2 decades), distribution of comorbidities in
the 2 cohorts.
An important finding of this study is that the
HRQOL of patients undergoing RIC or MAC was
similar in the majority of the domains and symptoms
at baseline and at 12months. These data are reassuring
for the referring physicians, as there is often concern
expressed over the HRQOL of older patients and
Figure 3. Longitudinal comparisons of HRQOL of patients undergoing myeloablative versus RIC. (A) FACT-An (80-point scale). (B) FACT-BMT
(40-point scale).
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ing HCT. The trajectory of decline and recovery of
HRQOL was also similar in the 2 cohorts at 1 year,
apart from a few differences. Both cohorts showed
lowest HRQOL scores in most domains on day 30
posttransplantation and a slow and gradual improve-
ment toward baseline scores over 6 to 12 months.
Physical function in the RIC cohort was better at day
30, which is probably related to lower RRT and earlier
hematopoietic recovery. A higher proportion of pa-
tients undergoing RIC had worsening of cognitive
function scores from day 100 onward, even though
cognitive function scores were similar in the 2 cohorts
at baseline. There was no significant association be-
tween occurrence of acute or cGVHD or duration of
GVHD treatment in the 2 arms (data not shown). A
significantly higher proportion of older patients in
the RIC cohort may explain this observation. Older
patients may have less cognitive reserve, and poten-
tially be prone to toxicities resulting from condition-
ing, calcineurin inhibitors, steroids, and infectious
complications. An exploratory analysis of cognitive
functioning in a relatively small sample size of patients
age 41 to 59 years did not show any consistent pattern.
Correlation with objective neuropsychologic testing
would be important in future studies.
Two other studies have evaluated longitudinal
QOL in patients undergoing RIC and compared with
MAC [17,18]. A study from the National Institutes of
Health evaluated longitudinal QOL in 76 patients
undergoing HCT (RIC, 41; MAC, 35) and reported
similar patterns of HRQOL in the 2 cohorts [17].A major shortcoming of this study was the significant
imbalance between the 2 cohorts in terms of disease
indications for which HCT was performed. The study
included patients with hematologic and nonhemato-
logic malignancies; and patients with acute leukemia
were mainly treated with MAC. Another study from
Sweden evaluated 56 patients (RIC, 31; myeloablative,
25) and reported similar HRQOL at 1 year. This study
included patients with a mixture of hematologic malig-
nancies, nonmalignant blood disorders, and solid tu-
mors. Several methodologic issues, such as clinical
relevance of differences in HRQOL and handling of
missing data, were not well addressed in these studies.
Several cautions need to be exercised in the inter-
pretation of our findings. It is difficult to exclude a se-
lection bias in favor of referring fitter older patients for
HCT. Allocation of conditioning intensity was based
on patient-related factors, such as older age, comor-
bidities, and performance scores, rather than random-
ization. The patients who were considered unsuitable
candidates for MAC were offered RIC. This could
introduce biases related to physicians, perceptions of
these conditioning regimens. Objective criteria for
the allocation of RIC in preference toMAC are not de-
fined at present and remain controversial. Although
randomization represents an ideal method to avoid
these biases, it is not feasible in older patients, given
the toxicities of MAC.
The strengths of this study are related to the pro-
spective design and comprehensive assessment of
HRQOL using reliable and well-validated cancer-
specific instruments. The study population is relatively
Table 6. Comparison of Changes in HRQOL Scores over Time in Patients Undergoing Myeloablative or Reduced-Intensity Con-
ditioning
Outcome Response
Baseline to Day 30 Baseline to Day 100 Baseline to Day 180 Baseline to Day 365
MAC
n 5 38
RIC
n 5 56
MAC
n 5 35
RIC
n 5 46
MAC
n 5 30
RIC
n 5 37
MAC
n 5 22
RIC
n 5 31
Global health Improved 21% 11% 34% 22% 43% 27% 45% 35%
Unchanged 29% 45% 26% 37% 23% 30% 18% 35%
Worse 50% 45% 40% 41% 37% 43% 36% 29%
P 5 .21 P 5 .37 P 5 .39 P 5 .41
Physical functioning Improved 11% 1.8% 17% 15% 17% 13% 32% 23%
Unchanged 21% 55% 46% 50% 30% 51% 41% 52%
Worse 68% 43% 37% 35% 53% 36% 27% 26%
P 5 .001 P 5 .91 P 5 .22 P 5 .72
Role functioning Improved 26% 21% 46% 30% 50% 36% 45% 52%
Unchanged 24% 23% 17% 16% 13% 31% 23% 23%
Worse 50% 55% 37% 43% 37% 33% 32% 26%
P 5 .89 P 5 .37 P 5 .25 P 5 .93
Emotional functioning Improved 34% 30% 31% 35% 23% 35% 32% 42%
Unchanged 47% 61% 43% 54% 57% 51% 41% 48%
Worse 18% 9% 26% 11% 20% 14% 27% 10%
P 5 .29 P 5 .22 P 5 .53 P 5 .30
Cognitive functioning Improved 18% 14% 46% 17% 40% 19% 36% 6%
Unchanged 26% 13% 34% 41% 47% 35% 41% 42%
Worse 55% 13% 20% 41% 13% 46% 23% 52%
P 5 .29 P 5 .02 P 5 .01 P 5 .01
Social functioning Improved 26% 21% 43% 33% 43% 38% 55% 48%
Unchanged 24% 25% 14% 28% 23% 27% 18% 26%
Worse 50% 54% 43% 39% 33% 35% 27% 26%
P 5 .85 P 5 .31 P 5 .91 P 5 .87
Fatigue Improved 68% 61% 51% 48% 47% 46% 45% 39%
Unchanged 16% 27% 20% 26% 23% 28% 18% 29%
Worse 16% 12% 29% 26% 30% 26% 36% 32%
P 5 .48 P 5 .84 P 5 .91 P 5 .73
FACT-An Improved 26% 16% 34% 26% 37% 28% 55% 32%
Unchanged 13% 29% 23% 26% 10% 18% 5% 19%
Worse 61% 55% 43% 48% 53% 54% 41% 48%
P 5 .16 P 5 .77 P 5 .63 P 5 .15
FACT-BMT Improved 18% 18% 14% 41% 23% 31% 27% 43%
Unchanged 24% 26% 34% 25% 23% 42% 27% 33%
Worse 58% 43% 51% 34% 53% 28% 45% 23%
P 5 .30 P 5 .03 P 5 .10 P 5 .28
HADS-Anxiety Improved 19% 18% 18% 13% 17% 15% 24% 19%
Unchanged 35% 39% 38% 50% 48% 38% 33% 32%
Worse 46% 43% 44% 37% 34% 46% 43% 48%
P 5 .96 P 5 .61 P 5 .65 P 5 .93
HADS-Depression Improved 35% 36% 35% 26% 41% 31% 19% 12%
Unchanged 54% 45% 32% 48% 24% 31% 48% 44%
Worse 11% 20% 32% 26% 34% 38% 33% 23%
P 5 .53 P 5 .40 P 5 .68 P 5 .75
IADL Improved 23% 15% 35% 38% 30% 46% 38% 25%
Unchanged 5.4% 19% 15% 31% 30% 22% 19% 20%
Worse 73% 67% 50% 31% 40% 32% 43% 37%
P 5 .19 P 5 .15 P 5 .45 P 5 .93
MAC indicates myeloablative conditioning; RIC, reduced-intensity conditioning; HRQOL, health-related quality of life.
Note: P values based on the Fisher exact test.
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ous studies for HRQOL data [17,18] and the study
benefits from a high completion rate of HRQOL
assessments. The main reason for noncompletion of
HRQOL assessment was sickness resulting from
transplant-related toxicities or disease relapse; patient
refusal or consent withdrawal was small. The collec-
tion of HRQOL data requires active patient participa-
tion, which is difficult although not impossible to
achieve when patients are very ill. Keeping this in
mind, we captured prospectively the reasons fornoncompletion of HRQOL assessments. Additionally,
we imputed missing data in a worst-case sensitivity
analysis to attempt to account for missing data. This
did not materially alter our findings, suggesting that
response bias was not a major issue.
In summary, our study confirms that the clinical
outcomes and HRQOL in patients with myeloid ma-
lignancies undergoing RIC are not inferior to MAC.
The trajectory of decline and recovery of HRQOL
in the 2 cohorts is similar. Extended follow-up of this
study is in progress to assess the impact of long-term
Biol Blood Marrow Transplant 18:113-124, 2012 123Outcomes and QOL after Myeloablative or RICcomplications such as cGVHD on HRQOL in these
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